Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways

Chia-Ling Gau, Juran Kato-Stankiewicz, Chen Jiang, Susie Miyamoto, Lea Guo and Fuyuhiko Tamanoi
Chia-Ling Gau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juran Kato-Stankiewicz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chen Jiang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susie Miyamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lea Guo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fuyuhiko Tamanoi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-04-0347 Published June 2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, Tsc-null mouse embryonic fibroblasts have a higher level of S6K phosphorylation than control mouse embryonic fibroblasts in serum-starved conditions. Cells were starved for 24 h (−). Cells were starved and then stimulated for 15 min with 20% fetal bovine serum (+). Phosphorylated and total levels of S6K were examined as described in Materials and Methods. Results are representative of three independent experiments. B, growth of Tsc1−/− and control mouse embryonic fibroblasts in serum-free medium (left); growth of Tsc2−/− and control mouse embryonic fibroblasts in serum-free medium (right). Twenty-four hours after seeding, cells were changed to medium without serum. Cell viability was assayed using an MTT assay. Points, means; bars, SD. C, Tsc2−/− mouse embryonic fibroblasts do not arrest in G0/G1 during serum starvation. Tsc2 mouse embryonic fibroblasts were collected at 60% confluency, whereas they were exponentially growing in normal medium or after serum starvation for 24 h. Cell cycle profile was then analyzed as described in Materials and Methods. Results are representative of three independent experiments. D, cell cycle profile of Tsc2−/− mouse embryonic fibroblasts were analyzed in exponentially growing conditions (48 h, 60% confluency) or in contact inhibited conditions (72 h, 100% confluent). Results are representative of three independent experiments.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    A, FTIs inhibit the farnesylation of Rheb. pCDNA3mycHA-Rheb (WT and C181S) were transiently expressed in human embryonic kidney-293 cells. Cells were treated for 24 h with the indicated concentration of FTI starting 16 h after transfection. Rheb expression was detected by immunoblotting with anti-myc 9B11 antibody. Results shown are representative of three independent experiments. B, farnesylation is required for the activation of S6K by Rheb. pCMV5-hemagglutinin-Rheb (WT and C181S) and pCMV5-Flag-p70S6K were transiently coexpressed in COS-7 cells. Cells were pretreated with the indicated concentration of BMS-225975 for 24 h, and then starved in PBS for 30 min. Phosphorylated and total levels of S6K were examined as described in Materials and Methods. Rheb expression was confirmed by the use of anti-hemagglutinin antibody. C, Tsc1−/− mouse embryonic fibroblasts (left) and Tsc2−/− mouse embryonic fibroblasts (right) were treated with 1 or 2 μmol/L BMS-225975 or 10 nmol/L rapamycin in serum-free medium for 48 h. Phosphorylated and total levels of S6K or S6 were examined as described in Materials and Methods. Inhibition of farnesylation was confirmed by the mobility shift of HDJ-2 protein. Results are representative of three independent experiments. D, Tsc−/− mouse embryonic fibroblasts were plated in 96-well plates, and after 24 h, medium was changed to serum-free medium and the indicated drug (day 0). Cells were treated with 1 μmol/L BMS-214662 or BMS-225975, or 10 nmol/L rapamycin. Cell viability was then assayed by MTT assay at the indicated times. Tsc1−/− mouse embryonic fibroblasts (left) and Tsc2−/− mouse embryonic fibroblasts (right). Points, means; bars, SD.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    FTIs can inhibit the anchorage-independent growth of Tsc−/− mouse embryonic fibroblasts. A, Tsc-null mouse embryonic fibroblasts are able to grow in soft agar. Mouse embryonic fibroblasts were cultured in soft agar for 2 wks at different densities, i.e., 3 × 103 cells per well (top) or 3 × 104 cells per well (bottom). Results are representative of three independent experiments. B, Tsc1−/− mouse embryonic fibroblasts (top) and Tsc2−/− mouse embryonic fibroblasts (bottom) were cultured for 2 wks in soft-agar in the presence of various inhibitors as indicated (0.25 μmol/L FTIs, 2.5 nmol/L rapamycin or 33 μmol/L LY249002). Results are representative of three independent experiments.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    FTIs induced the rearrangement of actin cytoskeleton in Tsc2−/− mouse embryonic fibroblasts. Tsc2 mouse embryonic fibroblasts were treated with DMSO, FTIs (2 μmol/L) or rapamycin (10 nmol/L) for 72 h in normal growth medium. Actin filaments of Tsc2+/+ (left) and Tsc2−/− (right) mouse embryonic fibroblasts were visualized by TRITC-phalloidin as indicated in Materials and Methods. Results are representative of three independent experiments.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Tsc2−/− mouse embryonic fibroblasts overexpressing myc-tagged Rheb (M184L) are resistant to FTI-induced rearrangement of actin cytoskeleton. Overnight after transfection, cells were treated with or without FTIs (2 μmol/L) and actin filaments were visualized by TRITC-phalloidin as described in Materials and Methods (left). Rheb expressing cells detected by anti-myc antibody and FITC anti-mouse antibody are indicated with arrows (right). Results are representative of three independent experiments.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 4 (6)
June 2005
Volume 4, Issue 6
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways
Chia-Ling Gau, Juran Kato-Stankiewicz, Chen Jiang, Susie Miyamoto, Lea Guo and Fuyuhiko Tamanoi
Mol Cancer Ther June 1 2005 (4) (6) 918-926; DOI: 10.1158/1535-7163.MCT-04-0347

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways
Chia-Ling Gau, Juran Kato-Stankiewicz, Chen Jiang, Susie Miyamoto, Lea Guo and Fuyuhiko Tamanoi
Mol Cancer Ther June 1 2005 (4) (6) 918-926; DOI: 10.1158/1535-7163.MCT-04-0347
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Identification of a small topoisomerase I–binding peptide that has synergistic antitumor activity with 9-aminocamptothecin
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement